Investor updates Suchbegriff Suchen Löschen 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 12 Januar 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab mehr Published on: 12 Januar 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer mehr Published on: 11 Januar 2021 Save the date: Roche Diagnostics Investor Day 2021 - Tuesday 23rd March 2021 mehr Published on: 11 Januar 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer mehr Published on: 11 Januar 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years mehr Published on: 5 Januar 2021 Invitation to Roche’s Full Year Results 2020 Presentation mehr Published on: 5 Januar 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer mehr
Published on: 12 Januar 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab mehr
Published on: 12 Januar 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer mehr
Published on: 11 Januar 2021 Save the date: Roche Diagnostics Investor Day 2021 - Tuesday 23rd March 2021 mehr
Published on: 11 Januar 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer mehr
Published on: 11 Januar 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years mehr
Published on: 5 Januar 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer mehr